The role of BST-2/Tetherin in host protection and disease manifestation

Immunity, Inflammation and Disease

Volumn 4, Issue 1, 2016, Pages 4-23

  Mahauad Fernandez, Wadie D ^a,b   Okeoma, Chioma M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Antagonists; Breast cancer; BST 2; Cancer; HIV 1; Malignancies; Tethering; Viruses

Indexed keywords

EID: 85063656201     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.92     Document Type: Review

References (187)

1. Goto, T., S. J. Kennel, M. Abe, M. Takishita, M. Kosaka, A. Solomon, and S. Saito. 1994. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84:1922-1930.
2. Swiecki, M., Y. Wang, S. Gilfillan, D. J. Lenschow, and M. Colonna. 2012. Cutting edge: paradoxical roles of BST2/tetherin in promoting type I IFN response and viral infection. J. Immunol. 188:2488-2492.
3. Liberatore, R. A., and P. D. Bieniasz. 2011. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc. Natl. Acad. Sci. USA 108:18097-18101.
4. Jones, P. H., H. V. Mehta, M. Maric, R. J. Roller, and C. M. Okeoma. 2012. Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology 9:10.
5. Erikson, E., T. Adam, S. Schmidt, J. Lehmann-Koch, B. Over, C. Goffinet, C. Harter, I. Bekeredjian-Ding, S. Sertel, F. Lasitschka, et al. 2011. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1. 24/tetherin in humans. Proc. Natl. Acad. Sci. USA 108:13688-13693.
6. Van Damme, N., D. Goff, C. Katsura, R. L. Jorgenson, R. Mitchell, M. C. Johnson, E. B. Stephens, and J. Guatelli. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 3:245-252.
7. Neil, S. J., T. Zang, and P. D. Bieniasz. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
8. Jones, P. H., and C. M. Okeoma. 2013. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated BST-2/Tetherin regulation. Cell. Signal. 25:2752-2761.
9. Kupzig, S., V. Korolchuk, R. Rollason, A. Sugden, A. Wilde, and G. Banting. 2003. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709.
10. Hammonds, J., J. J. Wang, H. Yi, and P. Spearman. 2010. Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog. 6:e000749.
11. Andrew, A. J., E. Miyagi, S. Kao, and K. Strebel. 2009. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 6:80.
12. Ishikawa, J., T. Kaisho, H. Tomizawa, B. O. Lee, Y. Kobune, J. Inazawa, K. Oritani, M. Itoh, T. Ochi, K. Ishihara, et al. 1995. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26:527-534.
13. Masuyama, N., T. Kuronita, R. Tanaka, T. Muto, Y. Hirota, A. Takigawa, H. Fujita, Y. Aso, J. Amano, and Y. Tanaka. 2009. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J. Biol. Chem. 284:15927-15941.
14. Galao, R. P., A. Le Tortorec, S. Pickering, T. Kueck, and S. J. Neil. 2012. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe. 12:633-644.
15. Tokarev, A., M. Skasko, K. Fitzpatrick, and J. Guatelli. 2009. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res. Hum. Retroviruses. 25:1197-1210.
16. Matsuda, A., Y. Suzuki, G. Honda, S. Muramatsu, O. Matsuzaki, Y. Nagano, T. Doi, K. Shimotohno, T. Harada, E. Nishida, et al. 2003. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 22:3307-3318.
17. Cocka, L. J., and P. Bates. 2012. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog. 8:e002931.
18. Swiecki, M., S. M. Scheaffer, M. Allaire, D. H. Fremont, M. Colonna, and T. J. Brett. 2011. Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J. Biol. Chem. 286:2987-2997.
19. Hinz, A., N. Miguet, G. Natrajan, Y. Usami, H. Yamanaka, P. Renesto, B. Hartlieb, A. A. McCarthy, J. P. Simorre, H. Gottlinger, et al. 2010. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe. 7:314-323.
20. Schubert, H. L., Q. Zhai, V. Sandrin, D. M. Eckert, M. Garcia-Maya, L. Saul, W. I. Sundquist, R. A. Steiner, C. P. Hill. 2010. Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc. Natl. Acad. Sci. USA 107:17951-17956.
21. Ohtomo, T., Y. Sugamata, Y. Ozaki, K. Ono, Y. Yoshimura, S. Kawai, Y. Koishihara, S. Ozaki, M. Kosaka, T. Hirano, et al. 1999. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258:583-591.
22. Perez-Caballero, D., T. Zang, A. Ebrahimi, M. W. McNatt, D. A. Gregory, M. C. Johnson, and P. D. Bieniasz. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511.
23. Fujita, H., K. Fujimoto, K. Tokunaga, and Y. Tanaka. 2012. Intracellular logistics of BST-2/Tetherin. Curr. HIV Res. 10:321-326.
24. Rollason, R., V. Korolchuk, C. Hamilton, P. Schu, and G. Banting. 2007. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J. Cell Sci. 120:3850-3858.
25. Fritz, J. V., N. Tibroni, O. T. Keppler, and O. T. Fackler. 2012. HIV-1 Vpu’s lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin. Virology 424:33-44.
26. Lopez, L. A., S. J. Yang, C. M. Exline, S. Rengarajan, K. G. Haworth, and P. M. Cannon. 2012. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol. 86:5467-5480.
27. Sarojini, S., T. Theofanis, and C. S. Reiss. 2011. Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. DNA Cell Biol. 30:965-974.
28. Jones, P. H., M. Maric, M. N. Madison, W. Maury, R. J. Roller, and C. M. Okeoma. 2013. BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Virology 438:37-49.
29. Ooi, Y. S., M. Dube, and M. Kielian. 2015. BST2/tetherin inhibition of alphavirus exit. Viruses 7:2147-2167.
30. Radoshitzky, S. R., L. Dong, X. Chi, J. C. Clester, C. Retterer, K. Spurgers, J. H. Kuhn, S. Sandwick, G. Ruthel, K. Kota, et al. 2010. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 84:10569-10580.
31. Lopez, L. A., S. J. Yang, H. Hauser, C. M. Exline, K. G. Haworth, J. Oldenburg, and P. M. Cannon. 2010. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol. 84:7243-7255.
32. Kuhl, A., C. Banning, A. Marzi, J. Votteler, I. Steffen, S. Bertram, I. Glowacka, A. Konrad, M. Sturzl, J. T. Guo, et al. 2011. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 204(Suppl 3):S850-S860.
33. Douglas, J. L., J. K. Gustin, K. Viswanathan, M. Mansouri, A. V. Moses, and K. Fruh. 2010. The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog. 6:e000913.
34. Yondola, M. A., F. Fernandes, A. Belicha-Villanueva, M. Uccelini, Q. Gao, C. Carter, and P. Palese. 2011. Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol. 85:2480-2491.
35. Miyakawa, K., S. Matsunaga, K. Watashi, M. Sugiyama, H. Kimura, N. Yamamoto, M. Mizokami, T. Wakita, and A. Ryo. 2015. Molecular dissection of HBV evasion from restriction factor tetherin: a new perspective for antiviral cell therapy. Oncotarget 6:21840-21852.
36. Pan, X. B., J. C. Han, X. Cong, and L. Wei. 2012. BST2/tetherin inhibits dengue virus release from human hepatoma cells. PloS ONE 7:e1033.
37. Pan, X. B., X. W. Qu, D. Jiang, X. L. Zhao, J. C. Han, and L. Wei. 2013. BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells. Antiviral Res. 98:54-60.
38. Amet, T., D. Byrd, N. Hu, Q. Sun, F. Li, Y. Zhao, S. Hu, A. Grantham, and Q. Yu. 2014. BST-2 expression in human hepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus. Curr. Mol. Med. 14:349-360.
39. Lim, E. S., and M. Emerman. 2009. Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST-2. J. Virol. 83:11673-11681.
40. Yin, X., Z. Hu, Q. Gu, X. Wu, Y. H. Zheng, P. Wei, and X. Wang. 2014. Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein. J. Virol. 88:1259-1270.
41. Hotter, D., D. Sauter, and F. Kirchhoff. 2013. Emerging role of the host restriction factor tetherin in viral immune sensing. J. Mol. Biol. 425:4956-4964.
42. Santa-Marta, M., P. M. de Brito, A. Godinho-Santos, and J. Goncalves. 2013. Host factors and HIV-1 replication: clinical evidence and potential therapeutic approaches. Front. Immunol. 4:343.
43. Fitzpatrick, K., M. Skasko, T. J. Deerinck, J. Crum, M. H. Ellisman, and J. Guatelli. 2010. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog. 6:e000701.
44. Habermann, A., J. Krijnse-Locker, H. Oberwinkler, M. Eckhardt, S. Homann, A. Andrew, K. Strebel, and H. G. Krausslich. 2010. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J. Virol. 84:4646-4658.
45. Mahauad-Fernandez, W. D., P. H. Jones, and C. M. Okeoma. 2014. Critical role for BST-2 in acute Chikungunya virus infection. J. Gen. Virol 95:2450-2461.
46. Tokarev, A., M. Suarez, W. Kwan, K. Fitzpatrick, R. Singh, and J. Guatelli. 2013. Stimulation of NF-kappaB activity by the HIV restriction factor BST2. J. Virol. 87:2046-2057.
47. Galao, R. P., S. Pickering, R. Curnock, and S. J. Neil. 2014. Retroviral retention activates a Syk-dependent HemITAM in human tetherin. Cell Host Microbe. 16:291-303.
48. Zhang, J., and C. Liang. 2010. BST-2 diminishes HIV-1 infectivity. J. Virol. 84:12336-12343.
49. Xagorari, A., and K. Chlichlia. 2008. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol. J. 2:49-59.
50. Chu, H., J. J. Wang, M. Qi, J. J. Yoon, X. Chen, X. Wen, J. Hammonds, L. Ding, and P. Spearman. 2012. Tetherin/BST-2 is essential for the formation of the intracellular virus-containing compartment in HIV-infected macrophages. Cell Host Microbe. 12:360-372.
51. Giese, S., and M. Marsh. 2014. Tetherin can restrict cell-free and cell-cell transmission of HIV from primary macrophages to T cells. PLoS Pathog. 10:e004189.
52. Kuhl, B. D., R. D. Sloan, D. A. Donahue, T. Bar-Magen, C. Liang, and M. A. Wainberg. 2010. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 7:115.
53. Casartelli, N., M. Sourisseau, J. Feldmann, F. Guivel-Benhassine, A. Mallet, A. G. Marcelin, J. Guatelli, and O. Schwartz. 2010. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog. 6:e000955.
54. Pham, T. N., S. Lukhele, F. Hajjar, J. P. Routy, and E. A. Cohen. 2014. HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and B ST2. Retrovirology 11:15.
55. Arias, J. F., L. N. Heyer, B. von Bredow, K. L. Weisgrau, B. Moldt, D. R. Burton, E. G. Rakasz, and D. T. Evans. 2014. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA 111:6425-6430.
56. Alvarez, R. A., R. E. Hamlin, A. Monroe, B. Moldt, M. T. Hotta, G. Rodriguez Caprio, D. S. Fierer, V. Simon, and B. K. Chen. 2014. HIV-1 Vpu antagonism of Tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J. Virol. 88:6031-6046.
57. Liu, C. C., P. M. Persechini, and J. D. Young. 1995. Perforin and lymphocyte-mediated cytolysis. Immunol. Rev. 146:145-175.
58. Li, S. X., B. S. Barrett, K. J. Heilman, R. J. Messer, R. A. Liberatore, P. D. Bieniasz, G. Kassiotis, K. J. Hasenkrug, and M. L. Santiago. 2014. Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. J. Immunol. 193:306-316.
59. Strebel, K., T. Klimkait, and M. A. Martin. 1988. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241:1221-1223.
60. Cohen, E. A., E. F. Terwilliger, J. G. Sodroski, and W. A. Haseltine. 1988. Identification of a protein encoded by the vpu gene of HIV-1. Nature 334:532-534.
61. Willey, R. L., F. Maldarelli, M. A. Martin, and K. Strebel. 1992. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 66:7193-7200.
62. Willey, R. L., F. Maldarelli, M. A. Martin, and K. Strebel. 1992. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J. Virol. 66:226-234.
63. Klimkait, T., K. Strebel, M. D. Hoggan, M. A. Martin, and J. M. Orenstein. 1990. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 64:621-629.
64. Strebel, K., T. Klimkait, F. Maldarelli, and M. A. Martin. 1989. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J. Virol. 63:3784-3791.
65. Terwilliger, E. F., E. A. Cohen, Y. C. Lu, J. G. Sodroski, and W. A. Haseltine. 1989. Functional role of human immunodeficiency virus type 1 vpu. Proc. Natl. Acad. Sci. USA 86:5163-5167.
66. Varthakavi, V., R. M. Smith, S. P. Bour, K. Strebel, and P. Spearman. 2003. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc. Natl. Acad. Sci. USA 100:15154-15159.
67. Bartee, E., A. McCormack, and K. Fruh. 2006. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2:e07.
68. Schubert, U., S. Bour, A. V. Ferrer-Montiel, M. Montal, F. Maldarell, and K. Strebel. 1996. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J. Virol. 70:809-819.
69. Paul, M., S. Mazumder, N. Raja, and M. A. Jabbar. 1998. Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells. J. Virol. 72:1270-1279.
70. Gupta, R. K., S. Hue, T. Schaller, E. Verschoor, D. Pillay, and G. J. Towers. 2009. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 5:e000443.
71. McNatt, M. W., T. Zang, T. Hatziioannou, M. Bartlett, I. B. Fofana, W. E. Johnson, S. J. Neil, and P. D. Bieniasz. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5:e000300.
72. Rong, L., J. Zhang, J. Lu, Q. Pan, R. P. Lorgeoux, C. Aloysius, F. Guo, S. L. Liu, M. A. Wainberg, and C. Liang. 2009. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 83:7536-7546.
73. Miyagi, E., A. J. Andrew, S. Kao, and K. Strebel. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. USA 106:2868-2873.
74. Goffinet, C., I. Allespach, S. Homann, H. M. Tervo, A. Habermann, D. Rupp, L. Oberbremer, C. Kern, N. Tibroni, S. Welsch, et al. 2009. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe. 5:285-297.
75. Mitchell, R. S., C. Katsura, M. A. Skasko, K. Fitzpatrick, D. Lau, A. Ruiz, E. B. Stephens, F. Margottin-Goguet, R. Benarous, and J. C. Guatelli. 2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5:e000450.
76. Douglas, J. L., K. Viswanathan, M. N. McCarroll, J. K. Gustin, K. Fruh, and A. V. Moses. 2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a TrCP-dependent mechanism. J. Virol. 83:7931-7947.
77. Blanchet, F. P., J. P. Mitchell, and V. Piguet. 2012. Beta-TrCP dependency of HIV-1 Vpu-induced downregulation of CD4 and BST-2/Tetherin. Curr. HIV Res. 10:307-314.
78. Schubert, U., T. Schneider, P. Henklein, K. Hoffmann, E. Berthold, H. Hauser, G. Pauli, and T. Porstmann. 1992. Human-immunodeficiency-virus-type-1-encoded Vpu protein is phosphorylated by casein kinase II. Eur. J. Biochem. 204:875-883.
79. Rollason, R., K. Dunstan, P. G. Billcliff, P. Bishop, P. Gleeson, H. Wise, P. Digard, and G. Banting. 2013. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation. PLoS ONE 8:e5680.
80. Neutzner, M., and A. Neutzner. 2012. Enzymes of ubiquitination and deubiquitination. Essays Biochem. 52:37-50.
81. Janvier, K., A. Pelchen-Matthews, J. B. Renaud, M. Caillet, M. Marsh, and C. Berlioz-Torrent. 2011. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog. 7:e001265.
82. Janvier, K., N. Roy, and C. Berlioz-Torrent. 2012. Role of the endosomal ESCRT machinery in HIV-1 Vpu-induced down-regulation of BST2/Tetherin. Curr. HIV Res. 10:315-320.
83. Raiborg, C., and H. Stenmark. 2009. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458:445-452.
84. Mayers, J. R., I. Fyfe, A. L. Schuh, E. R. Chapman, J. M. Edwardson, and A. Audhya. 2011. ESCRT-0 assembles as a heterotetrameric complex on membranes and binds multiple ubiquitinylated cargoes simultaneously. J. Biol. Chem. 286:9636-9645.
85. Dejucq, N., G. Simmons, and P. R. Clapham. 2000. T-cell line adaptation of human immunodeficiency virus type 1 strain S F162: effects on envelope, vpu and macrophage-tropism. J. Gen. Virol. 81:2899-2904.
86. Gaines, H., M. A. von Sydow, L. V. von Stedingk, G. Biberfeld, B. Bottiger, L. O. Hansson, P. Lundbergh, A. B. Sonnerborg, J. Wasserman, and O. O. Strannegaard. 1990. Immunological changes in primary HIV-1 infection. AIDS 4:995-999.
87. Lehmann, M., S. Rocha, B. Mangeat, F. Blanchet, I. H. Uji, J. Hofkens, and V. Piguet. 2011. Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction. PLoS Pathog. 7:e002456.
88. Arias, J. F., Y. Iwabu, and K. Tokunaga. 2012. Sites of action of HIV-1 Vpu in BST-2/Tetherin downregulation. Curr. HIV Res. 10:283-291.
89. Dube, M., B. B. Roy, P. Guiot-Guillain, J. Binette, J. Mercier, A. Chiasson, and E. A. Cohen. 2010. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6:e000856.
90. Andrew, A. J., E. Miyagi, and K. Strebel. 2011. Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J. Virol. 85:2611-2619.
91. Schmidt, S., J. V. Fritz, J. Bitzegeio, O. T. Fackler, and O. T. Keppler. 2011. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio 2:e00011-e00036.
92. Lewinski, M. K., M. Jafari, H. Zhang, S. J. Opella, and J. Guatelli. 2015. Membrane anchoring by a C-terminal tryptophan enables HIV-1 Vpu to displace bone marrow stromal antigen 2 (BST2) from sites of viral assembly. J. Biol. Chem. 290:10919-10933.
93. Hauser, H., L. A. Lopez, S. J. Yang, J. E. Oldenburg, C. M. Exline, J. C. Guatelli, and P. M. Cannon. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51.
94. Le Tortorec, A., and S. J. Neil. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83:11966-11978.
95. Bour, S., U. Schubert, K. Peden, and K. Strebel. 1996. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J. Virol. 70:820-829.
96. Ritter Jr., G. D., G. Yamshchikov, S. J. Cohen, and M. J. Mulligan. 1996. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J. Virol. 70:2669-2673.
97. Bour, S., and K. Strebel. 1996. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J. Virol. 70:8285-8300.
98. Abada, P., B. Noble, and P. M. Cannon. 2005. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J. Virol. 79:3627-3638.
99. Noble, B., P. Abada, J. Nunez-Iglesias, and P. M. Cannon. 2006. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J. Virol. 80:2924-2932.
100. Lau, D., W. Kwan, and J. Guatelli. 2011. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J. Virol. 85:9834-9846.
101. Gustin, J. K., Y. Bai, A. V. Moses, and J. L. Douglas. 2015. Ebola virus glycoprotein promotes enhanced viral egress by preventing Ebola VP 40 from associating with the host restriction factor BST2/Tetherin. J. Infect. Dis. 212:181-190.
102. Yasuda, J. 2012. Ebolavirus replication and Tetherin/BST-2. Front. Microbiol. 3:111.
103. Mansouri, M., K. Viswanathan, J. L. Douglas, J. Hines, J. Gustin, A. V. Moses, and K. Fruh. 2009. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 83:9672-9681.
104. Liu, Y., S. Luo, S. He, M. Zhang, P. Wang, C. Li, W. Huang, B. Hu, G. E. Griffin, R. J. Shattock, et al. 2015. Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins. Virology 475:96-109.
105. Blondeau, C., A. Pelchen-Matthews, P. Mlcochova, M. Marsh, R. S. Milne, and G. J. Towers. 2013. Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M. J. Virol. 87:13124-13133.
106. Viswanathan, K., M. S. Smith, D. Malouli, M. Mansouri, J. A. Nelson, and K. Fruh. 2011. BST2/Tetherin enhances entry of human cytomegalovirus. PLoS Pathog. 7:e002332.
107. Bampi, C., L. Rasga, and L. Roux. 2013. Antagonism to human BST-2/tetherin by Sendai virus glycoproteins. J. Gen. Virol. 94:1211-1219.
108. Lv, M., B. Zhang, Y. Shi, Z. Han, Y. Zhang, Y. Zhou, W. Zhang, J. Niu, and X. F. Yu. 2015. Identification of BST-2/tetherin-induced hepatitis B virus restriction and hepatocyte-specific BST-2 inactivation. Sci. Rep. 5:11736.
109. Serra-Moreno, R., K. Zimmermann, L. J. Stern, and D. T. Evans. 2013. Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis. PLoS Pathog. 9:e003487.
110. Zhang, F., W. N. Landford, M. Ng, M. W. McNatt, P. D. Bieniasz, and T. Hatziioannou. 2011. SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathog. 7:e002039.
111. Zhang, F., S. J. Wilson, W. C. Landford, B. Virgen, D. Gregory, M. C. Johnson, J. Munch, F. Kirchhoff, P. D. Bieniasz, and T. Hatziioannou. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe. 6:54-67.
112. Roeth, J. F., M. Williams, M. R. Kasper, T. M. Filzen, and K. L. Collins. 2004. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J. Cell Biol. 167:903-913.
113. Jin, Y. J., C. Y. Cai, X. Zhang, H. T. Zhang, J. A. Hirst, and S. J. Burakoff. 2005. HIV Nef-mediated CD4 down-regulation is adaptor protein complex 2 depen. J. Immunol. 175:3157-3164.
114. Manes, T. D., S. Hoer, W. A. Muller, P. J. Lehner, and J. S. Pober. 2010. Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins block distinct steps in transendothelial migration of effector memory CD4+ T cells by targeting different endothelial proteins. J. Immunol. 184:5186-5192.
115. Pardieu, C., R. Vigan, S. J. Wilson, A. Calvi, T. Zang, P. Bieniasz, P. Kellam, G. J. Towers, and S. J. Neil. 2010. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog. 6:e000843.
116. Watanabe, R., G. P. Leser, and R. A. Lamb. 2011. Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology 417:50-56.
117. Mangeat, B., L. Cavagliotti, M. Lehmann, G. Gers-Huber, I. Kaur, Y. Thomas, L. Kaiser, and V. Piguet. 2012. Influenza virus partially counteracts restriction imposed by Tetherin/BST-2. J. Biol. Chem. 287:22015-22029.
118. Bruce, E. A., T. E. Abbink, H. M. Wise, R. Rollason, R. P. Galao, G. Banting, S. J. Neil, and P. Digard. 2012. Release of filamentous and spherical influenza A virus is not restricted by tetherin. J. Gen. Virol. 93:963-969.
119. Mahauad-Fernandez, W. D., N. C. Borcherding, W. Zhang, and C. M. Okeoma. 2015. Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells. PLoS ONE 10:e123931.
120. Fang, K. H., H. K. Kao, L. M. Chi, Y. Liang, S. C. Liu, C. Hseuh, C. T. Liao, T. C. Yen, J. S. Yu, and K. P. Chang. 2014. Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer. Laryngoscope 124:E354-E360.
121. Wang, W., Y. Nishioka, S. Ozaki, A. Jalili, S. Abe, S. Kakiuchi, M. Kishuku, K. Minakuchi, T. Matsumoto, and S. Sone. 2009. HM1. 24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1. 24 antibody. Cancer Immunol. Immunother. 58:967-976.
122. Mahauad-Fernandez, W. D., K. A. DeMali, A. K. Olivier, and C. M. Okeoma. 2014. Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasi. Breast Cancer Res. 16(6):493, doi: 10.1186/s13058-014-0493-8.
123. Sayeed, A., G. Luciani-Torres, Z. Meng, J. L. Bennington, D. H. Moore, and S. H. Dairkee. 2013. Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells. PLoS ONE 8:e7191.
124. Milutin Gasperov, N., S. A. Farkas, T. K. Nilsson, and M. Grce. 2014. Epigenetic activation of immune genes in cervical cancer. Immunol. Lett. 162:256-257.
125. Tai, Y. T., H. M. Horton, S. Y. Kong, E. Pong, H. Chen, S. Cemerski, M. J. Bernett, D. H. Nguyen, S. Karki, S. Y. Chu, et al. 2012. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1. 24 antibody against multiple myeloma via augmented effector function. Blood 119:2074-2082.
126. Staudinger, M., P. Glorius, R. Burger, C. Kellner, K. Klausz, A. Gunther, R. Repp, W. Klapper, M. Gramatzki, and M. Peipp. 2014. The novel immunotoxin HM1. 24-ETA’ induces apoptosis in multiple myeloma cells. Blood Cancer J. 4:e19.
127. Yokoyama, T., T. Enomoto, S. Serada, A. Morimoto, S. Matsuzaki, Y. Ueda, K. Yoshino, M. Fujita, S. Kyo, K. Iwahori, et al. 2012. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Int. J. Cancer 132:472-484.
128. Wainwright, D. A., I. V. Balyasnikova, Y. Han, and M. S. Lesniak. 2011. The expression of BST2 in human and experimental mouse brain tumors. Exp. Mol. Pathol. 91:440-446.
129. Cai, D., J. Cao, Z. Li, X. Zheng, Y. Yao, W. Li, and Z. Yuan. 2009. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 9:102.
130. Gu, G., D. Zhao, and Z. Yin. 2012. P. BST-2 binding with cellular MT1-MMP blocks cell growth and migration via decreasing MMP2 activity. J. Cell Biochem. 113:1013-1021.
131. Mahauad-Fernandez, W. D., K. A. DeMali, A. K. Olivier, and C. M. Okeoma. 2014. Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis. Breast Cancer Res. 16:493.
132. Yoo, H., S. H. Park, S. K. Ye, and M. Kim. 2011. IFN-gamma-induced BST2 mediates monocyte adhesion to human endothelial cells. Cell Immunol. 267:23-29.
133. Kim, Y. N., K. H. Koo, J. Y. Sung, U. J. Yun, and H. Kim. 2012. Anoikis resistance: an essential prerequisite for tumor metastasis. Int. J. Cell Biol. 2012:306879.
134. Tan, K., D. Goldstein, P. Crowe, and J. L. Yang. 2013. Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis. J. Cancer Res. Clin. Oncol. 139:1795-1805.
135. Ozaki, S., M. Kosaka, M. Harada, H. Nishitani, M. Odomi, and T. Matsumoto. 1998. Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24. Cancer 82:2184-2190.
136. Harada, T., S. Ozaki, A. Oda, D. Tsuji, A. Ikegame, M. Iwasa, K. Udaka, S. Fujii, S. Nakamura, H. Miki, et al. 2013. Combination with a defucosylated anti-HM1. 24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors. PloS ONE 8:e3905.
137. Harada, T., and S. Ozaki. 2014. Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. Biomed. Res. Int. 2014:965384.
138. Wang, W., Y. Nishioka, S. Ozaki, A. Jalili, V. K. Verma, M. Hanibuchi, S. Abe, K. Minakuchi, T. Matsumoto, and S. Sone. 2009. Chimeric and humanized anti-HM1. 24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer 63:23-31.
139. Kawai, S., Y. Azuma, E. Fujii, K. Furugaki, S. Ozaki, T. Matsumoto, M. Kosaka, and H. Yamada-Okabe. 2008. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci. 99:2461-2466.
140. Miyagi, E., A. Andrew, S. Kao, T. Yoshida, and K. Strebel. 2011. Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells. J. Virol. 85:11981-11994.
141. Epeldegui, M., B. Blom, and C. H. Uittenbogaart. 2015. BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur. J. Immunol. 45:728-737.
142. Zou, J., W. Li, A. Misra, F. Yue, K. Song, Q. Chen, G. Guo, J. Yi, J. T. Kimata, and L. Liu. 2015. The viral restriction factor tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) from association with beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy. J. Biol. Chem. 290:7269-7279.
143. Li, X., D. Kaloyanova, M. van Eijk, R. Eerland, G. van der Goot, V. Oorschot, J. Klumperman, F. Lottspeich, V. Starkuviene, F. T. Wieland, et al. 2007. Involvement of a Golgi-resident GPI-anchored protein in maintenance of the Golgi structure. Mol. Biol. Cell 18:1261-1271.
144. Billcliff, P. G., R. Rollason, I. Prior, D. M. Owen, K. Gaus, and G. Banting. 2013. CD317/tetherin is an organiser of membrane microdomains. J. Cell Sci. 126:1553-1564.
145. Bego, M. G., J. Mercier, and E. A. Cohen. 2012. Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J. Virol. 86:3513-3527.
146. Savan, R., S. Ravichandran, J. R. Collins, M. Sakai, and H. A. Young. 2009. Structural conservation of interferon gamma among vertebrates. Cytokine Growth Factor Rev. 20:115-124.
147. Hu, Z., X. Wu, J. Ge, and X. Wang. 2013. Inhibition of virus replication and induction of human tetherin gene expression by equine IFN-alpha1. Veter. Immunol. Immunopathol. 156:107-113.
148. Thippeshappa, R., H. Ruan, W. Wang, P. Zhou, and J. T. Kimata. 2013. A variant macaque-tropic human immunodeficiency virus type 1 is resistant to alpha interferon-induced restriction in pig-tailed macaque CD4+ T cells. J. Virol. 87:6678-6692.
149. Ge, Y., A. A. Dombkowski, K. M. LaFiura, D. Tatman, R. S. Yedidi, M. L. Stout, S. A. Buck, G. Massey, D. L. Becton, H. J. Weinstein, et al. 2006. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107:1570-1581.
150. Cao, W., L. Bover, M. Cho, X. Wen, S. Hanabuchi, M. Bao, D. B. Rosen, Y. H. Wang, J. L. Shaw, Q. Du, et al. 2009. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 206:1603-1614.
151. Wenzel, J., B. Bekisch, M. Uerlich, O. Haller, T. Bieber, and T. Tuting. 2005. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am. J. Clin Pathol. 124:37-48.
152. Dunn, G. P., C. M. Koebel, and R. D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6:836-848.
153. Jones, P. H., W. D. Mahauad-Fernandez, M. N. Madison, and C. M. Okeoma. 2013. BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer. Virology 444:124-139.
154. Guzzo, C., M. Jung, A. Graveline, B. W. Banfield, and K. Gee. 2012. IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN. Sci. Rep. 2:974.
155. Kastelein, R. A., C. A. Hunter, and D. J. Cua. 2007. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25:221-242.
156. Fakruddin, J. M., R. A. Lempicki, R. J. Gorelick, J. Yang, J. W. Adelsberger, A. J. Garcia-Pineres, L. A. Pinto, H. C. Lane, and T. Imamichi. 2007. Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood 109:1841-1849.
157. Imamichi, T., J. Yang, D. W. Huang, T. W. Brann, B. A. Fullmer, J. W. Adelsberger, R. A. Lempicki, M. W. Baseler, and H. C. Lane. 2008. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. AIDS 22:39-45.
158. Greenwell-Wild, T., N. Vazquez, W. Jin, Z. Rangel, P. J. Munson, and S. M. Wahl. 2009. Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. Blood 114:1864-1874.
159. Perissi, V., N. Menini, E. Cottone, D. Capello, M. Sacco, F. Montaldo, and M. De Bortoli. 2000. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 19:280-288.
160. Zhou, Y., X. Wang, M. Liu, Q. Hu, L. Song, L. Ye, D. Zhou, and W. Ho. 2010. A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages. Immunology 131:40-49.
161. Sang, M., J. B. Liu, M. Dai, J. G. Wu, and W. Z. Ho. 2014. Toll-like receptor 3 signaling inhibits simian immunodeficiency virus replication in macrophages from Rhesus macaques. Antiviral Res. 112:103-112.
162. Homann, S., D. Smith, S. Little, D. Richman, and J. Guatelli. 2011. Upregulation of BST-2/Tetherin by HIV infection in vivo. J. Virol. 85:10659-10668.
163. Bauerfeld, C. P., R. Rastogi, G. Pirockinaite, I. Lee, M. Hüttemann, B. Monks, M. J. Birnbaum, L. Franchi, G. Nuñez, and L. Samavati. 2012. TLR4-mediated AKT activation is Myd88/TRIF dependent and critical for induction of oxidative phosphorylation and mitochondrial transcription factor a in murine macrophages. J. Immunol. 188:2847-2857.
164. Arbibe, L., J. P. Mira, N. Teusch, L. Kline, M. Guha, N. Mackman, P. J. Godowski, R. J. Ulevitch, and U. G. Knaus. 2000. Toll-like receptor 2-mediated NF-κB activation requires a Rac I-dependent pathway. Nat. Immunol. 1:533-540.
165. Blanchet, F. P., R. Stalder, M. Czubala, M. Lehmann, L. Rio, B. Mangeat, and V. Piguet. 2013. TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse. Retrovirology 10:6.
166. Jarrossay, D., G. Napolitani, M. Colonna, F. Sallusto, and A. Lanzavecchia. 2001. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 31:3388-3393.
167. Kadowaki, N., S. Ho, S. Antonenko, R. W. Malefyt, R. A. Kastelein, F. Bazan, and Y. J. Liu. 2001. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194:863-869.
168. Liu, Y. J. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23:275-306.
169. Gilliet, M., W. Cao, and Y. J. Liu. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8:594-606.
170. Colonna, M., G. Trinchieri, and Y. J. Liu. 2004. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5:1219-1226.
171. Piqueras, B., J. Connolly, H. Freitas, A. K. Palucka, and J. Banchereau. 2006. Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood 107:2613-2618.
172. Cao, W., and L. Bover. 2010. Signaling and ligand interaction of IL T7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol. Rev. 234:163-176.
173. Jeffries, M. A., M. Dozmorov, Y. Tang, J. T. Merrill, J. D. Wren, and A. H. Sawalha. 2011. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 6:593-601.
174. Barriocanal, M., E. Carnero, V. Segura, and P. Fortes. 2014. Long non-coding RNA BST2/BISPR is induced by IFN and regulates the expression of the antiviral factor Tetherin. Front. Immunol. 5:655.
175. Kambara, H., L. Gunawardane, E. Zebrowski, L. Kostadinova, R. Jobava, D. Krokowski, M. Hatzoglou, D. D. Anthony, and S. Valadkhan. 2014. Regulation of interferon-stimulated gene BST2 by a lncRNA transcribed from a shared bidirectional promoter. Front Immunol. 5:676.
176. Okeoma, C. M., N. Lovsin, B. M. Peterlin, and S. R. Ross. 2007. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445:927-930.
177. Okeoma, C. M., A. L. Huegel, J. Lingappa, M. D. Feldman, and S. R. Ross. 2010. APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe. 8:534-543.
178. Kim, H. H., S. M. Grande, J. G. Monroe, and S. R. Ross. 2012. Mouse mammary tumor virus suppresses apoptosis of mammary epithelial cells through ITAM-mediated signaling. J. Virol. 86:13232-13240.
179. Kim, H. H., A. P. van den Heuvel, J. W. Schmidt, and S. R. Ross. 2011. Novel common integration sites targeted by mouse mammary tumor virus insertion in mammary tumors have oncogenic activity. PLoS ONE 6:e7425.
180. Ross, S. R. 2010. Mouse mammary tumor virus molecular biology and oncogenesis. Viruses 2:2000-2012.
181. Melana, S. M., M. A. Picconi, C. Rossi, J. Mural, L. V. Alonio, A. Teyssie, J. F. Holland, and B. G. Pogo. 2002. [Detection of murine mammary tumor virus (MMTV) env gene-like sequences in breast cancer from Argentine patients]. Medicina 62:323-327.
182. Wang, Y., J. F. Holland, I. J. Bleiweiss, S. Melana, X. Liu, I. Pelisson, A. Cantarella, K. Stellrecht, S. Mani, and B. G. Pogo. 1995. Detection of mammary tumor virus env gene-like sequences in human breast cancer. Cancer Res. 55:5173-5179.
183. Zammarchi, F., M. Pistello, A. Piersigilli, R. Murr, C. Di Cristofano, A. G. Naccarato, and G. Bevilacqua. 2006. MMTV-like sequences in human breast cancer: a fluorescent PCR/laser microdissection approach. J Pathol. 209:436-444.
184. Melana, S. M., I. Nepomnaschy, M. Sakalian, A. Abbott, J. Hasa, J. F. Holland, and B. G. Pogo. 2007. Characterization of viral particles isolated from primary cultures of human breast cancer cells. Cancer Res. 67:8960-8965.
185. Wang, Y., J. D. Jiang, D. Xu, Y. Li, C. Qu, J. F. Holland, and B. G. Pogo. 2004. A mouse mammary tumor virus-like long terminal repeat superantigen in human breast cancer. Cancer Res. 64:4105-4111.
186. Feldman, D., M. Roniger, A. Bar-Sinai, O. Braitbard, C. Natan, D. C. Love, J. A. Hanover, and J. Hochman. 2012. The signal peptide of mouse mammary tumor virus-env: a phosphoprotein tumor modulator. Mol Cancer Res. 10:1077-1086.
187. Yang, S. J., L. A. Lopez, C. M. Exline, K. G. Haworth, and P. M. Cannon. 2011. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 8:78.